Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Prostatic Neoplasms 1 Neoplasms, Plasma Cell 1 Multiple Myeloma 1 Metastatic Non-hematologic Malignancies 1 Mesothelioma, Malignant 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 51 Ipilimumab 50 Cyclophosphamide 43 Nivolumab 41 aldesleukin 30 Interleukin-2 23 Vemurafenib 20 fludarabine 19 Temozolomide 18 fludarabine phosphate 15 dabrafenib 15 trametinib 12 spartalizumab 10 Radiotherapy 10 Radiosurgery 10 Dacarbazine 10 CTLA-4 Antigen 10 cobimetinib 9 binimetinib 9 poly ICLC 7 encorafenib 7 Paclitaxel 7 atezolizumab 6 Introns 6 Biopsy 6 montanide ISA 51 5 Carboplatin 5 epacadostat 4 MART-1 Antigen 4 Interferon alpha-2 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Melanoma × vatalanib × Clear all

NCT00615160 2021-10-06

PTK/ZK in Disseminated Malignant Melanoma

University Hospital Schleswig-Holstein

Phase 1/2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡